Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
Ki Mun Kang, Bae Kwon Jeong, In Bong Ha, Gyu Young Chai, Gyeong Won Lee, Hoon Gu Kim, Jung Hoon Kang, Won Seob Lee, Myoung Hee Kang
Radiat Oncol J. 2012;30(3):140-145.   Published online 2012 Sep 30     DOI: https://doi.org/10.3857/roj.2012.30.3.140
Citations to this article as recorded by Crossref logo
Radiotherapy Dose and Induction Chemotherapy Cycles Are Associated With Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
Liyao Chen, Yu Hou, Yaoxiong Xia, Li Chang, Xianmin Diao, Li Wang, Lan Li, Qing Long, Ying Liu, Yan Liu, Wenhui Li
Technology in Cancer Research & Treatment.2020; 19: 153303382095180.     CrossRef
Prognostic value of pretreatment Glasgow prognostic score in stage IIIB geriatric non-small cell lung cancer patients undergoing radical chemoradiotherapy
Erkan Topkan, Yasemin Bolukbasi, Yurday Ozdemir, Ali Ayberk Besen, Hüseyin Mertsoylu, Ugur Selek
Journal of Geriatric Oncology.2019; 10(4): 567.     CrossRef
Assessment of the External Validity of the National Comprehensive Cancer Network and European Society for Medical Oncology Guidelines for Non–Small-Cell Lung Cancer in a Population of Patients Aged 80 Years and Older
Nicolò Matteo Luca Battisti, Marina Sehovic, Martine Extermann
Clinical Lung Cancer.2017; 18(5): 460.     CrossRef
Normal lung sparing Tomotherapy technique in stage III lung cancer
Chae-Seon Hong, Sang Gyu Ju, Yong Chan Ahn, Gyu Sang Yoo, Jae Myoung Noh, Dongryul Oh, Kwangzoo Chung, Hongryull Pyo, Kwanghyun Jo
Radiation Oncology.2017;[Epub]     CrossRef
Distinctive Patterns of Initially Presenting Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non-Small Cell Lung Cancer
Dong Soo Lee, Yeon S. Kim, Chul S. Kay, Sung H. Kim, Chang D. Yeo, Jin W. Kim, Seung Joon Kim, Young K. Kim, Yoon H. Ko, Jin H. Kang, Kyo Y. Lee
Medicine.2016; 95(6): e2795.     CrossRef
Definitive radiotherapy alone over 60 Gy for patients unfit for combined treatment to stage II-III non-small cell lung cancer: retrospective analysis
Ji Hyeon Joo, Si Yeol Song, Su Ssan Kim, Yuri Jeong, Seong-Yun Jeong, Wonsik Choi, Eun Kyung Choi
Radiation Oncology.2015;[Epub]     CrossRef
Radical Oncological Surgery and Adjuvan Therapy in Non-Small Cell Lung Cancer Patients over 70 years of Age
Nilgun Yilmaz Demirci, Sukran Ulger, Ulku Yilmaz, Koray Aydogdu, Aydin Yilmaz, Yurdanur Erdogan
Asian Pacific Journal of Cancer Prevention.2015; 16(11): 4711.     CrossRef
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced Non–Small-Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
Hans H. Strøm, Roy M. Bremnes, Stein H. Sundstrøm, Nina Helbekkmo, Ulf Aasebø
Clinical Lung Cancer.2015; 16(3): 183.     CrossRef
Changes in non-surgical management of stage III non-small cell lung cancer at a single institution between 2003 and 2010
Ellen J. F. van Reij, Max Dahele, Peter M. van de Ven, Patricia F. de Haan, Wilko F. A. R. Verbakel, Egbert F. Smit, Ben J. Slotman, Suresh Senan
Acta Oncologica.2014; 53(3): 316.     CrossRef
Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non–small cell lung cancer
Mun Sem Liew, Joseph Sia, Maud H. W. Starmans, Ali Tafreshi, Sam Harris, Malcolm Feigen, Shane White, Allan Zimet, Philippe Lambin, Paul C. Boutros, Paul Mitchell, Thomas John
Cancer Medicine.2013; 2(6): 916.     CrossRef